

FP187: DMF for Multiple Sclerosis

JMP Securities Life Science Conference

June 22, 2016




Forward-Looking Statements



This presentation contains forward-looking statements about Forward Pharma A/S based on management's current expectations which are subject to known and unknown uncertainties and risks. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, our ability to raise additional financing on favorable terms, the success of our clinical trials, our ability to obtain regulatory approval of FP187, our success in maintaining and defending our patent estate and other risk factors included in our filings with the U.S. Securities and Exchange Commission. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.

FWP – The Investment Opportunity



Introduction to Forward Pharma




- Focused on DMF since 2004
- FP187: Proprietary slow release formulation of DMF
- 480 mg daily dose in MS patent application allowable and '871 patent interference ongoing
- RRMS Phase 3 trial in preparation
- IPO priced 10/14/2014, raised \$235 M in gross proceeds
- Well capitalized to pursue patent and development strategies

FP187 Clinical Differentiation

- FP187 utilizes the same active pharmaceutical ingredient as Tecfidera®
- FP187 utilizes an “erosion matrix” formulation


Formulation Differentiation



Tecfidera® RRMS Global Sales



\$US mln



- Cumulative sales are \$8.4 billion
- The only approved dose for RRMS is 480 mg/day

Source: Biogen Inc.

USPTO and EPO Claims Covering 480 mg/day




6 separate patent applications with claims to 480 mg/day with the same priority date of at least as early as October 7, 2005

	Application Number	Description
US	11/576,871	Treating MS with DMF at 480 mg/day * Interference declared; FWP as Senior Party – 4/13/15
	14/213,399	Up-titration of DMF to 480 mg/day doses for the treatment of MS Final rejection issued subject to further action by us
	14/212,503	Treating MS with DMF at 480 mg/day to reach certain MMF levels in the bloodstream Final rejection issued subject to further action by us
European	EP14172398.1	Treating MS with 480 mg/day of DMF wherein the pH controlled release compositions have an enteric coat * Issued – 5/20/15; Patent #EP2801355
	EP14172396.5	Treating MS with 480 mg/day of controlled release DMF Negative search report issued by EPO
	EP14172390.8	Treating MS with 480 mg/day of controlled release DMF with particular in vitro dissolution profile Positive search report issued by EPO

Forward Pharma Detailed Timeline: 2004-2008



FP187 core composition patent applications filed at least 1 year, 4 months, 1 day earlier



- **Interference declared April 13, 2015**

A patent interference is an administrative proceeding at the USPTO used to determine which party is the first to invent a common invention claimed by both parties

- **Forward awarded “Senior Party” status**


The Senior Party has the earliest effective filing date to the common invention; entitled to the presumption that it is the first inventor

- **Interference is ongoing**

The interference was “redeclared” on August 19, 2015, confirming Forward as the Senior Party

Updated Interference Process

- Compressed timeline: combined phases, no district court appeal route
- Final decision expected in 2018



Senior vs. Junior Party

- **Forward Pharma: “Senior Party”**
 - Has the earliest effective filing date to the invention; entitled to the presumption that it invented first
- **Biogen: “Junior Party”**
 - Has the burden of proof to show a date of invention that predates our invention
 - Has the burden to show (a) conception prior to Forward’s earliest effective filing date, and (b) diligent reduction to practice of the invention from a time just prior to Forward’s earliest effective filing date

480 mg/day for MS: Forward Pharma '871 and Biogen '514

Forward Pharma US '871

- A method of treating...multiple sclerosis comprising orally administering ...(a) a therapeutically effective amount of dimethyl fumarate...wherein the therapeutically effective amount...is **480 mg per day**
- **Filing date: 10/08/04**

Biogen Idec US '514

- A method of treating...multiple sclerosis comprising orally administering...a therapeutically effective amount of dimethyl fumarate...about **480 mg per day**
- **Earliest filing date: 02/08/07**

Summary Timeline for the Interference

- **August 8, 2016:** File all replies
- **November 30, 2016:** Default oral argument

Provisional rights

- **Potential royalty initiation date**
 - Forward's '871 claims were published on April 10, 2014
 - Biogen was provided a copy of Forward's published claims on September 8, 2014


Reasonable Royalty Determination

- Patentee who wins an infringement case is entitled to no less than a “reasonable royalty”
- Legal framework derives from a hypothetical negotiation between a willing licensor and a willing licensee on the eve of infringement
- Assuming the patent is valid and infringed:
 - What is the maximum the infringer would pay the patentee to be able to stay on the market?
 - What is the minimum the patentee would accept to allow the accused product to stay on the market?


Royalty Regimes

	Academic Inventor	Industrial Inventor
Competitive Product	NO	YES
Active R&D Spend	NO	YES
Ability to Commercialize	NO	YES
Opportunity Cost	LOW	HIGH
Royalty	LOW	HIGH
Example	Cabilly	Late-stage Biotech Deals

Potential FP187 Patent Protection in the US



Potential FP187 Patent Protection in Europe



10 years regulatory exclusivity

+1 year if approved in second indication with clinical benefit over existing therapies



German Utility Model and '355 Patent Infringement

- Two lawsuits alleging infringement by Biogen's marketing of Tecfidera® in Germany at the 480 mg dose
 - Forward Pharma filed a lawsuit against Biogen on November 18, 2014 on the Utility Model
 - The granted European '355 patent was added to the Utility Model lawsuit at the Regional Court in Dusseldorf
- An oral hearing in Germany originally scheduled for March 24, 2016 at the Regional Court in Dusseldorf has been stayed (i.e. postponed) under a mutual agreement between the parties

Erosion Matrix Patent Family


Forward Pharma has 3 issued patents covering its erosion matrix family, all expiring in 2030

- **EP2379063** (covering erosion matrix formulations with a thin enteric coating) has been upheld by the Opposition Division of the EPO, subject to appeal, after oppositions by multiple third parties, including Biogen, were rejected by the EPO on April 5, 2016
- **EP2564839** (covering erosion matrix formulations with a particular composition) was granted by the EPO on May 11, 2016
- **U.S. Patent No 8,906,420** (“Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix”) was issued on December 9, 2014

Support for our IP

- **US:** The USPTO has twice found 480 mg/day to treat MS allowable as an invention; the PTAB declared an interference with Forward Pharma as the Senior Party
- **Europe:** The '8.1 EU patent application issued as patent EP2801355

BIIB to FWP Current Relative Valuation




* As of 6/20/2016

**Citigroup estimate 2013 – 2028; report 2/24/16

314 patients and healthy volunteers to date in completed FP187 clinical trials

Clinical Trials to Date




* No patients with MS treated to date with FP187

Current status of ongoing pharmaceutical development



API production

- API production continues
- Up-scaling to large batches completed
- Technology transfer to secondary supplier completed



Tablet production

- Secondary supplier of tablets identified, technology transfer ongoing
- Validation of increased batch size ongoing

Pre-clinical status

Currently conducting additional preclinical studies on:

- Reproductive toxicity
- Chronic toxicity
- Long-term carcinogenicity


Clinical trial status

- Phase I studies planned and ongoing
- Phase III MS in prep with CRO, sites being identified

Planned Phase 3 Trial in RRMS: FP187-MS-301

Trial Design

- Double-blind, double-dummy 48-week active comparator with two FP187 dosage groups



- One Phase 3 trial, 48 weeks, in alignment with FDA pre-IND meeting in August 2013
- IND for MS filed on April 30, 2014; FDA “may proceed” letter sent on June 10, 2014
- Also evaluating alternative Phase 3 clinical strategies in RRMS that could shorten our time to commercialization and/or reduce costs

Financial Position

Well capitalized following IPO with an efficient business model

Balance Sheet (\$)

	3/31/16
Cash and Investments	\$170.8 M

Income Statement (\$ in thousands)

	Quarter Ended March 31, 2016
R&D Expenses	\$9,682
G&A Expenses	2,958
Operating Loss	\$12,640

Management

- **Peder M. Andersen, MD**
Chief Executive Officer & Chief Operating Officer
 - More than 25 years of experience in the pharmaceutical industry
 - Several years of experience in business development, both generic and proprietary, in Europe
- **Andrzej Stano**
Executive Vice President, Pharmaceutical Development and Production
 - More than 30 years in the pharmaceutical industry, most recently at GlaxoSmithKline
 - Development and production of a wide range of products with extensive experience in solid oral dose and modified release technologies
- **Rupert Sandbrink, MD, PhD**
Executive Vice President, Multiple Sclerosis/Neurology and Immunology
 - More than 17 years in the pharmaceutical industry, most recently at Bayer AG
 - Expertise in all stages of clinical development, including launch and medical affairs
- **Joel Sendek**
Chief Financial Officer
 - 18 years as a sell-side analyst, most recently as Managing Director, Healthcare Equity Research, Stifel Financial Corp.
 - Former Head of Business Development, Progenics
 - Corporate Finance, Goldman Sachs
- **Tom Carbone**
Vice President, Finance and Controller
 - Over 30 years of experience providing auditing and accounting services to public and private companies, many within the biotechnology industry
 - Extensive experience with the reporting requirements for publicly listed companies
 - Involvement in numerous public and private financings including initial public offerings

Corporate Overview

Board of Directors

- **Florian Schönharting**
Chief Executive Officer, NB Capital
- **Torsten Goesch, MD, PhD**
Director, Rosetta Capital
- **Jan G. J. van de Winkel, PhD**
President and Chief Executive Officer, Genmab
- **Grant Hellier Lawrence**
Managing Director and Chief Financial Officer, Nunc A/S
- **Jakob Mosegaard Larsen**
Partner, Mazanti-Andersen Korsø Jensen
- **Karen Smith, MD, PhD**
Global Head of R&D and Chief Medical Officer, Jazz Pharmaceuticals
- **Duncan Moore, PhD**
Partner, East West Capital Partners

Scientific Advisors

- **Fred Lublin, MD**
Mount Sinai Hospital
- **Giancarlo Comi, MD**
Hospital San Raffaela, Milan
- **Kristian Reich, MD**
Dermatologikum Hamburg
- **Jerry Wolinsky, MD**
University of Texas, Medical School
- **Per Soelberg Sørensen, MD**
Rigshospitalet, Copenhagen University Hospital
- **Ulrich Mrowietz, MD**
Psoriasis-Center Kiel

Select Investors

- **Nordic Biotech**
- **BioScience Managers Limited**
- **The Baupost Group**
- **BVF Partners LP**

Key Upcoming Events

- **Interference proceeding progress at the USPTO**
- **US: Progress on 480 mg/day MS patent applications**
- **EU: Progress on 480 mg/day MS patent applications**
- **MS Phase 3 clinical development progress**